Anker SD; for the FAIR-HF Trial Investigators. The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF studyChronic heart failureIron deficiencyRenal functionFerric carboxymaltoseAimsAnaemia and iron deficiency are constituents of the cardio-renal syndrome in chronic...
Red cell distribution width (RDW), a measure of variability in red blood cell size, is a novel prognostic marker in chronic heart failure (CHF). Iron deficiency contributes to elevated RDW. In the FAIR-HF trial, i.v. ferric carboxymaltose (FCM) improved the 6 min walk test (6MWT) dista...
Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial Therapy with i.v. iron in patients with chronic heart failure (CHF) and iron deficiency (ID) improves symptoms, functional capacity, and quality of life...
Postop anemia in high-CV-risk patients: No CV gains from fixed hemoglobin target in trial Bypassing the blues: How simple collaborative care can help tackle depression after CABG surgery HeartMate II continuous-flow VAD sets new benchmark in destination-therapy trial FAIR-HF: Symptom improveme...
Iron deficiency and anaemia in heart failure: understanding the FAIR-HF trial. Eur J Heart Fail. 2010;12(11):1159–62.Jose Gonzalez-Costello,Josep Comin-Colet.Iron deficiency and anaemia in heart failure: understanding the FAIR-HF trial.EUROPEAN JOURNAL OF HEART FAILURE. 2010...
Cost-effectiveness of ferric carboxymaltose in patients with chronic heart failure: an analysis from the FAIR-HF trial (abstract no. P1437). Eur Heart J. 2010;31(Suppl 1):225.Blank, PR, Schwenkglenks, M, Szucs, TD (2010) Cost-effectiveness of ferric carboxymaltose in p...
摘要: Publication » PCV65 HEALTH ECONOMIC ASSESSMENT OF FERRIC CARBOXYMALTOSE IN PATIENTS WITH IRON DEFICIENCY AND CHRONIC HEART FAILURE IN THE FAIR-HF TRIAL.DOI: 10.1016/S1098-3015(11)72408-1 被引量: 41 年份: 2010 收藏 引用 批量引用 报错 分享 全部来源 免费下载 求助全文 Elsevier (...
Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. Eur J Heart Fail. 2013;15(11):1267-76.The effect of intravenous ferric carboxymaltose on red cell distribution width:a subanalysis of the FAIR-HF ...
17. - P. 329-339.Ponikowski P, Filippatos G, Colet JC, Willenheimer R, Dickstein K, Luscher T, Gaudesius G, von Eisenhart Rothe B, Mori C, Greenlaw N, Ford I, Macdougall I, Anker SD; FAIR-HF Trial Investigators. The impact of intravenous ferric carboxymaltose on renal function: ...
In: 43rd Annual Meeting of the American Society of Nephrology. Denver (CO); 2010. pp. 18-21.Ponikowski P, et al. The impact of intravenous ferric carboxymaltose on renal function: An analysis of the FAIR-HF study. Abstract presented at Late Breaking Trial Session, HFA 2010...